Myricx Bio
Latest round
- Series A
Last raised
- Jul 2024
Total raised
- $121M
Investors
- 7
About Myricx Bio
Founded in 2019 and headquartered in London, UK, Myricx Bio specializes in the development of antibody drug conjugates (ADCs) designed to improve cancer care.Myricx Bio specializes in the development of a novel class of antibody drug conjugates (ADCs) that utilize inhibitors of N-myristoyltransferases (NMT) as their key payloads. These innovative ADCs are designed to address significant unmet needs in oncology, providing targeted therapy for various solid tumor-associated antigens and cancer cell types. Myricx Bio's ADCs aim to enhance efficacy while maintaining safety, demonstrated by their strong preclinical performance.Myricx Bio engages in B2B transactions, primarily through partnerships with pharmaceutical companies and research institutions. These collaborations involve licensing agreements, where Myricx Bio provides its proprietary ADC technology for clinical development and commercialization. Revenue may come from milestone payments linked to the progress of ADC candidates in clinical trials, as well as royalties on sales once products are commercialized. The structure of these transactions could include fixed payments upon achieving regulatory milestones and ongoing royalties based on product sales. The company plans to expand its product offerings, with new ADCs targeting specific cancer therapies expected to enter development soon. Additionally, Myricx Bio aims to broaden its market reach in North America and Europe, seeking collaborations with pharmaceutical firms and research institutions to enhance their innovation in cancer treatment.
Who invested in Myricx Bio
7 investors across 2 rounds
See all investors in Myricx Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Myricx Bio
Who invested in Myricx Bio?
Myricx Bio has 7 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Myricx Bio raised?
Myricx Bio has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Myricx Bio last raise money?
Myricx Bio's most recent round on record is a Series A, in Jul 2024.
What does Myricx Bio do?
Founded in 2019 and headquartered in London, UK, Myricx Bio specializes in the development of antibody drug conjugates (ADCs) designed to improve cancer care.
Where is Myricx Bio headquartered?
Myricx Bio is headquartered in London, UK.
Which VCs invest in companies like Myricx Bio?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Myricx Bio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Myricx Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.